Analysts highlighted concerns about Charles River’s Contract Development and Manufacturing Organization (CDMO) business, along with concerns about the stock’s valuation relative to demand trends. The good news is that Moderna’s balance sheet, with $9.5 billion in cash and investments at the end of 2024, provides the financial flexibility to pursue these ambitious objectives. Following a steep sell-off, the stock now trades at a more balanced valuation of roughly 4 times sales as a price-to-sales (P/S) ratio, offering a potentially attractive entry point for investors convinced of the company’s long-term opportunity. As the company continues to advance its technologies and expand its strategic alliances, Moderna Inc. is proving to be a reliable source of transformative medicines to combat viruses and other diseases.

Shares of Ticketmaster parent Live Nation Entertainment (LYV) advanced 4.4%. Jericho Capital Asset Management recently included the live event company’s stock among its top picks, noting its strong performance in 2024, driven by a rise in concert events and attendees versus the prior year. Last week, Live Nation agreed to a $20 million settlement in a lawsuit filed by investors who alleged that the company failed to disclose risks related to business practices that raised antitrust concerns. Rakuten Securities Inc. grew its position in Moderna by 248.8% during the first quarter. Rakuten Securities Inc. now owns 26,160 shares of the company’s stock worth $742,000 after buying an additional 18,661 shares in the last quarter.

Moderna Stock Analysis – MarketRank™

• Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.
• Perhaps the most promising is mRNA-4157, a personalized therapeutic cancer vaccine in phase 3 trials for treating melanoma, along with renal cell carcinoma and bladder cancer in phase 2 studies.
• BDF Gestion bought a new stake in Moderna during the first quarter worth about $783,000.
• The boost to the buyout plan coincided with AIG’s investor day event, which also saw the company issue upbeat growth targets.
• Shares of U.S. biotech companies fell as much as 10% premarket on Monday following reports that a top vaccine official at the U.S.
• Moderna scored higher than 85% of companies evaluated by MarketBeat, and ranked 136th out of 916 stocks in the medical sector.

Upgrade to MarketBeat All Access to add more stocks to your watchlist. Sign-up to receive the latest news and ratings for Moderna and its competitors with MarketBeat’s FREE daily newsletter. Get an email with the top market-moving news in bullet point format, for free. A meeting of the Food and Drug Administration’s vaccine advisory committee to discuss the next season’s flu vaccine has reportedly been canceled, the trading forex beginners guide second such disruption of a meeting involving vacc…

UBS Group cut their price objective on shares of Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Evercore ISI set a $50.00 target price on Moderna in a report on Friday, February 14th. Finally, Berenberg Bank increased their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a report on Thursday, January 16th. Moderna is recognized as a pioneer in messenger RNA (mRNA) technology, seen as a potential game changer in medicine. This technology uses the body’s cellular machinery to fight diseases by directing cells to produce proteins that trigger a specific immune response or address a particular health issue. As proven by the success of the Spikevax COVID-19 vaccine, Moderna aims to build on this achievement by expanding into applications for influenza, cancer, and rare diseases.

Moderna (MRNA) Stock Price, News & Analysis

As a result, we can interpret positive estimate revisions as a good sign for the company’s business outlook. Total company revenue fell from a peak of $19.3 billion in 2022 to $3.2 billion for the full year ended Dec. 31, 2024. For 2025, Moderna forecasts total company sales of between $1.5 billion and $2.5 billion, reflecting its struggle to find a new blockbuster drug. The top executives of Moderna, Akamai, and FMC just bought stock on the open market. Stocks of major vaccine makers dropped on Monday after the Food and Drug Administration’s (FDA) top vaccine official Dr. Peter Marks resigned, citing conflicts with Health and Human Services (HHS) Sec…

Here are five things you should know if you’re considering buying Moderna stock now. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today’s markets. Moderna (MRNA) raised $499 million in an initial public offering on Friday, December 7th 2018. Morgan served as the underwriters for the IPO and BofA Merrill Lynch, Barclays, Piper Jaffray, Bryan, Garnier, Oddo BHF, Oppenheimer, Needham and Chardan were co-managers.

The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company was powertrend formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally.

Company Calendar

Moderna Inc. operates in multiple therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, autoimmune diseases and cardiovascular diseases. Its product pipeline includes prophylactic vaccines, localized regenerative therapeutics, cancer vaccines, systemic secreted therapeutics, intratumoral immuno-oncology and systemic intracellular therapeutics. The company is also developing vaccines and therapeutics for other infectious diseases, such as influenza, hMPV+PIV3, respiratory syncytial virus, endemic HCoV, cytomegalovirus, human immunodeficiency virus, herpes simplex virus, Epstein-Barr virus and varicella-zoster virus. The Goldman Sachs Group downgraded Moderna from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. JPMorgan Chase & Co. lowered their price target on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Friday, March 21st.

Moderna Inc., founded in 2010, is a biotechnology company focused on creating transformative medicines to combat viruses and other diseases. The company utilizes messenger ribonucleic acid (mRNA) technology, which transports information from a living creature’s DNA to other parts of the body. The company has experienced rapid growth due to its innovative mRNA technologies, especially as the U.S. authorized the COVID-19 vaccine developed by Moderna Inc. for human use in December 2020. This includes vaccines for norovirus and cytomegalovirus, with data readouts expected this year. Perhaps the most promising is mRNA-4157, a personalized therapeutic cancer vaccine in phase 3 trials for treating melanoma, along with renal cell carcinoma and bladder cancer in phase 2 studies.

• Global uptake has been slow, with low demand for its current indication to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection, generating just $25 million in sales last year.
• Elsewhere, the Dow lost 1.33%, while the tech-heavy Nasdaq lost 0.13%.
• Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A.
• Please bear with us as we address this and restore your personalized lists.

Marks, who participated in the development of the vaccines to protect against COVID-19, intends to step down by the end of this week, pointing to disagreements with Health and Human Services Secretary Robert F. Kennedy Jr. Moderna (MRNA) shares dropped nearly 12% following news that FDA official Peter Marks will step down on April 5th, causing uncertainty in the biotech sector, particularly for vaccine makers. Yahoo Finance Senior Reporter Anjalee Khemlani joins Morning Brief to discuss how this leadership change could impact companies like Moderna, Novavax (NVAX), and others in the healthcare industry. To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. Adding to Moderna’s woes, its highly anticipated respiratory syncytial virus (RSV) vaccine, known as mRESVI and approved by the Food and Drug Administration (FDA) in 2024 as the company’s only other commercialized product beyond Spikevax, has faced a sluggish rollout.

Trump’s tariffs are a new challenge for Big Pharma. Here are the best positioned stocks

QRG Capital Management Inc. boosted its position in Moderna by 16.1% in the first quarter. QRG Capital Management Inc. now owns 8,274 shares of the company’s stock valued at $235,000 after buying an additional 1,150 shares in the last quarter. BDF Gestion bought a new stake in Moderna during the first quarter worth about $783,000. Janney Montgomery Scott LLC increased its holdings in shares of Moderna by 37.1% during the first quarter. Janney Montgomery Scott LLC now owns 13,825 shares of the company’s stock worth $392,000 after buying an additional 3,744 shares in the last quarter.

After trading in the red for much of Monday’s session, the S&P 500 rallied in the afternoon to close 0.6% higher. The Dow ended with a daily gain of 1.0%, while the Nasdaq slipped 0.1%. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

Moderna scored higher than 85% of companies evaluated by MarketBeat, and ranked 136th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Moderna Inc. has formed strategic partnerships with a variety of pharmaceutical companies, including AstraZeneca PLC, Merck & Co. Furthermore, the company has a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Insider buying signals a market shift for Moderna, Inc. after years of relentless sales, with CEO Stephane Bancel purchasing MRNA shares due to perceived undervaluation. Shares of vaccine makers Moderna and Novavax, along with a range of other biotech companies, fell after the resignation of key FDA official Peter Marks.

Food and Drug Administration had resigned, fanning worries over slowe… According to 1 minute simple and profitable forex scalping strategy pdf 20 analysts, the average rating for MRNA stock is “Hold.” The 12-month stock price forecast is $54.47, which is an increase of 120.30% from the latest price. Discover which analysts rank highest on predicting the price target of MRNA.

The Trump administration is reviewing a contract extended to Moderna in the final days of the Biden administration. Major U.S. equities indexes were mixed to kick off the new trading week as U.S. trade policy remained in focus. Discover which analysts rank highest on predicting the directional movement of MRNA. Unlock stock picks and a broker-level newsfeed that powers Wall Street.